

Major Products

Innovative Pharmaceuticals Business

Brand Name (Generic Name)	Efficacy	Launched	Remarks
Japan Daiichi Sankyo Co., Ltd.			
<i>ENHERTU</i> (<i>trastuzumab deruxtecan</i>)	Anti-cancer agent (HER2 directed antibody drug conjugate)	2020	Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells.
<i>Tarlige</i> (<i>mirogabalin</i>)	Pain treatment	2019	An $\alpha 2\delta$ ligand. The pain therapy agent to reduce the neurotransmitter release from nerve terminals.
<i>CANALIA</i> (<i>teneligliptin / canagliflozin</i>)	Type 2 diabetes mellitus treatment	2017	A first combination drug of the DPP-4 inhibitor <i>teneligliptin</i> and the SGLT2 inhibitor <i>canagliflozin</i> approved in Japan, which demonstrates blood glucose-lowering activity through a complementary pharmacological effect.
<i>VIMPAT</i> (<i>lacosamide</i>)	Anti-epileptic agent	2016	Sodium channel blocker. Suppresses the excessive excitation of nerves in the brain, and reduces the occurrence of epileptic seizures.
<i>Effient</i> (<i>prasugrel</i>)	Antiplatelet agent	2014	ADP receptor inhibitor. Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion due to thrombosis.
<i>PRALIA</i> (<i>denosumab</i>)	Treatment for osteoporosis / inhibitor for rheumatoid arthritis-induced progression of bone erosion	2013	Human monoclonal anti-RANKL antibody. Subcutaneous formulation which controls bone resorption and bone destruction by specifically inhibiting RANKL.
<i>TENELIA</i> (<i>teneligliptin</i>)	Type 2 diabetes mellitus treatment	2012	DPP-4 inhibitor. The agent facilitates glucose-dependent insulin release and inhibits glucagon release, thereby demonstrating the blood glucose-lowering activity.
<i>RANMARK</i> (<i>denosumab</i>)	Treatment for bone disorders caused by bone metastases from tumors	2012	Human monoclonal anti-RANKL antibody. This controls abnormal bone destruction caused by osteoclasts, and reduces the occurrence of fractures and other skeletal related events (SRE). Approved for the indication of giant cell tumors of bone in 2014 and was designated as an orphan drug.
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2011	Orally active Factor Xa inhibitor. Prevents the formation of blood clots by specifically, reversibly and directly inhibiting the enzyme, Factor Xa, a clotting factor in the blood.
<i>NEXIUM</i> (<i>esomeprazole</i>)	Ulcer treatment	2011	Proton pump inhibitor. This can be used for a wide range of ages, from infants to adults. It suppresses excessive gastric acid secretion.
<i>Memary</i> (<i>memantine</i>)	Alzheimer's disease treatment	2011	N-methyl-D-aspartate (NMDA) receptor antagonist. <i>Memantine</i> slows down progression of dementia symptoms in patients with moderate to severe Alzheimer's disease.
<i>Inavir</i> (<i>laninamivir</i>)	Anti-influenza treatment	2010	Neuraminidase inhibitor that inhibits influenza viral proliferation. Treatment is completed with a single inhaled dosage.
<i>Olmotec</i> (<i>olmesartan</i>)	Antihypertensive agent	2004	Angiotensin II receptor blocker. This suppresses the vasoconstriction effects of angiotensin II, and thereby demonstrates the effect of lowering blood pressure.
<i>Rezaltas</i> (<i>olmesartan medoxomil</i>)	Antihypertensive agent	2010	A combination drug of two antihypertensive agents: an angiotensin II receptor blocker, <i>olmesartan medoxomil</i> , and a calcium ion antagonist, <i>azelnidipine</i> . This combination demonstrates the effect of decreasing blood pressure through a complementary pharmacological effect.
<i>Cravit</i> (<i>levofloxacin</i>)	Synthetic antibacterial agent	1993	New quinolone antibacterial agent offering strong antibacterial action and a broad antibacterial spectrum.
<i>Mevalotin</i> (<i>pravastatin</i>)	Hypercholesterolemia treatment	1989	HMG-CoA reductase inhibitor (statin) that lowers blood cholesterol levels by inhibiting cholesterol synthesis in the liver.
<i>Loxonin</i> (<i>loxoprofen</i>)	Anti-inflammatory analgesic	1986	Nonsteroidal anti-inflammatory analgesic. Suppresses the production of prostaglandin associated with inflammation, and thereby demonstrates an analgesic effect. Also available as transdermal agents (poultice, gel, tape).



LIXIANA (Japan)



TENELIA, CANALIA (Japan)



Memary (Japan)



Tarlige (Japan)



NEXIUM (Japan)



PRALIA (Japan)



RANMARK (Japan)



Enhertu (Japan)

Innovative Pharmaceuticals Business

Brand Name (Generic Name)	Efficacy	Launched	Remarks
US Daiichi Sankyo, Inc.			
<i>Enhertu</i> (<i>trastuzumab deruxtecan</i>)	Treatment for malignant tumors (anti-HER2 antibody drug conjugate)	2020	An antibody drug conjugate that combines a fully human monoclonal antibody with a payload drug through a linker. The human monoclonal antibody binds specifically to human epidermal growth factor receptor 2 (HER2), a member of cell growth factor family receptor. The payload is a potent topoisomerase I inhibitor that has high membrane permeability and also kills nearby cancer cells with a bystander effect.
<i>SAVAYSA</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally active Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE))
<i>Effient</i> (<i>prasugrel</i>)	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion
<i>Benicar</i> (<i>olmesartan</i>)	Antihypertensive agent	2002	<i>Benicar</i> : <i>Olmesartan</i>
<i>Benicar HCT</i> (<i>olmesartan medoxomil</i>)	Antihypertensive agent	2003	<i>Benicar HCT</i> : A combination drug of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>AZOR</i> (<i>olmesartan medoxomil</i>)	Antihypertensive agent	2007	<i>AZOR</i> : A combination drug of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>TRIBENZOR</i> (<i>olmesartan medoxomil, hydrochlorothiazide, and amlodipine besylate</i>)	Antihypertensive agent	2010	<i>TRIBENZOR</i> : A triple combination drug of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>
<i>Welchol</i> (<i>colesevelam</i>)	Hypercholesterolemia treatment / Type 2 diabetes mellitus treatment	2000	Bile acid sequestrant. Marketed as a drug for treatment of hypercholesterolemia. Gained approval also for type 2 diabetes mellitus indication as part of life-cycle management
US American Regent, Inc.			
<i>Injectafer</i> (<i>ferric carboxymaltose injection</i>)	Iron deficiency anemia treatment	2013	Effective for patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis-dependent chronic kidney disease
<i>Venofer</i> (<i>iron sucrose injection</i>)	Iron deficiency anemia treatment	2000	Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients, etc.
Europe Daiichi Sankyo Europe GmbH			
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally active Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications for the prevention of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of recurrent venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE))
<i>Effient</i> (<i>prasugrel</i>)	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion
<i>Olmotec</i> (<i>olmesartan</i>)	Antihypertensive agent	2002	<i>Olmotec</i> : <i>Olmesartan</i>
<i>Olmotec Plus</i> (<i>olmesartan medoxomil</i>)	Antihypertensive agent	2005	<i>Olmotec Plus</i> : A combination drug of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>Sevikar</i> (<i>olmesartan medoxomil</i>)	Antihypertensive agent	2009	<i>Sevikar</i> : A combination drug of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>Sevikar HCT</i> (<i>olmesartan medoxomil, hydrochlorothiazide, and amlodipine besylate</i>)	Antihypertensive agent	2010	<i>Sevikar HCT</i> : A triple combination drug of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>

Generic Business

Brand Name (Efficacy)
Japan Daiichi Sankyo Espha Co., Ltd.
<i>Olmecartan</i> (Antihypertensive agent)
<i>Silodosin</i> (Treatment for dysuria)
<i>Gefitinib</i> (Treatment for malignant tumors)
<i>Bicalutamide</i> (Prostate cancer treatment)
<i>Tamoxifen</i> (Anti-breast cancer agent)

Vaccine Business

Brand Name
Japan Daiichi Sankyo Co., Ltd.
<i>Influenza HA Vaccine</i>
<i>Live Attenuated Measles-Rubella Combined Vaccine</i>
<i>Live Attenuated Mumps Vaccine</i>
<i>Squarekids</i> (4-valent combination vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis (polio))
<i>H5N1 Influenza Vaccines</i>

OTC Related Business


Brand Name
Japan Daiichi Sankyo Healthcare Co., Ltd.
<i>Lulu</i> (Combination cold remedy)
<i>Loxonin S</i> (Antipyretic analgesic / topical anti-inflammatory analgesic)
<i>Transino</i> (Melasma improvement / treatment against spots and freckles)
<i>MINON</i> (Skincare)
<i>Breath Labo</i> (Oral care)
<i>Clean Dental</i> (Oral care)



Injectafer (US)



LIXIANA (Europe)



Silodosin (Generic Drugs)



MINON series (OTC Related Drugs)



Enhertu (US)



Gefitinib (Generic Drugs)



Lulu (OTC Related Drugs)



Influenza HA Vaccine (Vaccines)